Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer

被引：0
|
作者：
Yu, L. [1 ]
Xu, J. [1 ]
Qiao, R. [1 ]
Zhong, H. [1 ]
Han, B. [1 ]
Zhong, R. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
small-cell lung cancer; anlotinib; PD-1/PD-L1;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-10
引用
收藏
页码：S391 / S392
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer
    Yu, Lian
    Xu, Jianlin
    Qiao, Rong
    Han, Baohui
    Zhong, Hua
    Zhong, Runbo
    CANCER MEDICINE, 2023, 12 (05): : 5372 - 5383
  • [2] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
    Shang, X. Q.
    Wang, T.
    Chen, G.
    Ma, C.
    Wang, H.
    Jia, X.
    Mei, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1550 - S1550
  • [3] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
    Wang, Q.
    Ma, C.
    Wang, T.
    Chen, G.
    Wang, H.
    Mei, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1063 - S1063
  • [4] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated
    Wang, Q.
    Xu, A.
    Ma, C.
    Wang, T.
    Liu, P.
    Duan, Y.
    Kong, T.
    Chen, G.
    Jia, X.
    Shang, K.
    Yang, G.
    Zhang, G.
    Yu, F.
    Wang, H.
    Chen, H.
    ANNALS OF ONCOLOGY, 2023, 34
  • [5] Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non–small-cell lung cancer
    Li Liu
    Shuo Zhang
    Hai-Yan Yang
    Chun-Hua Zhou
    Yi Xiong
    Nong Yang
    Ye Tian
    Lipids in Health and Disease, 23
  • [6] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 818 - 830
  • [7] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hidetoshi Hayashi
    Kazuhiko Nakagawa
    International Journal of Clinical Oncology, 2020, 25 : 818 - 830
  • [8] Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
    Zhai, Xiaoyang
    Jing, Xuquan
    Li, Ji
    Tian, Yaru
    Xu, Shuhui
    Wang, Min
    Zhu, Hui
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [9] Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer
    Liu, Li
    Zhang, Shuo
    Yang, Hai-Yan
    Zhou, Chun-Hua
    Xiong, Yi
    Yang, Nong
    Tian, Ye
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [10] THE COST EFFECTIVENESS ANALYSIS OF PD-1 AND PD-L1 AGENTS COMPARED WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Bae-Shaaw, Y. H.
    Hay, J. W.
    VALUE IN HEALTH, 2018, 21 : S30 - S30
12345